Biocon Corporate Presentation

Biosimilars: Developing biologics for global markets at all scale Biocon Biologics Biosimilars are an attractive opportunity Robust biosimilar portfolio coupled with adjacent biologics (e.g., ADG20) Fully integrated - lab to market Global Footprint (120+ countries) Strong partners e.g., Viatris, Sandoz and Adagio Branded Formulations India (BFI) forms a robust commercial platform in India Therapeutic Areas Molecule Pegfilgrastim¹ Trastuzumab¹ Oncology Bevacizumab¹ Pertuzumab¹ 1,2 Immunology Diabetes Undisclosed 8 HE Approved Products6 Adalimumab¹ Etanercept¹,2 Glargine 100U¹,3 Glargine 300U¹ Aspart¹ RHI4 7 Assets 2 Research & Product Status S US Dev. Markets: ex-US MoW5 EU, CANZ EU, CANZ EU EU, CA, Japan EU EU, ANZ, Japan EU EU Early Dev./ Preclinical Clinical Filed Approved 30 Manufacturing sites Development sites (2 Bengaluru, 1 Malaysia) 25+ 1 CGMP approvals (incl. FDA & EMA) 1 In partnership with Viatris; 2 Partner Viatris has in-licensed product (Biocon benefits from economic interest); 3 Japan is outside of Viatris partnership; 4 RHI non-partnered asset completed Ph 1 and considering potential Ph 3 waiver to be confirmed with US FDA advice, shown as Planned submission; 5 MoW represents Most of the World markets. Chart represents the status of the country where the product is in most advanced stage. Every country has a different status; 6 Includes Adalimumab and Etanercept which have been in-licensed by Viatris and Biocon Biologics has economic interest. 12

View entire presentation